COVID-19: Unmasking Telemedicine.

Hare, Nathan; Bansal, Priya; Bajowala, Sakina S.; Abramson, Stuart L.; Chervinskiy, Sheva; Corriel, Robert; Hauswirth, David W.; Kakumanu, Sujani; Mehta, Reena; Rashid, Quratulain; Rupp, Michael R.; Shih, Jennifer; Mosnaim, Giselle S.

Abstract Telemedicine adoption has rapidly accelerated since the onset of the COVID-19 pandemic.1 Telemedicine provides increased access to medical care and helps to mitigate risk by conserving personal protective equipment and providing for social/physical distancing in order to continue to treat patients with a variety of allergic and immunologic conditions. During this time, many allergy and immunology clinicians have needed to adopt telemedicine expeditiously in their practices while studying the complex and variable issues surrounding its regulation and reimbursement. Some concerns have been temporarily alleviated since March 2020 to aid with patient care in the setting of COVID-19. Other changes are ongoing at the time of this publication. Members of the Telemedicine Work Group in the American Academy of Allergy, Asthma & Immunology (AAAAI) completed a telemedicine literature review of online and Pub Med resources through May 9, 2020 to detail Pre-COVID-19 telemedicine knowledge and outline up to date telemedicine material. This work group report was developed to provide guidance to allergy/immunology clinicians as they navigate the swiftly evolving telemedicine landscape.